The new Alzheimer's drug: Why Donanemab, yet to be approved, has generated excitement
Within
a year, a second drug has been found effective in checking cognitive decline
in people with early Alzheimer's. Developed by the pharmaceutical giant Eli
Lilly, Donanemab was found to slow down cognitive decline by 35% when
compared with a ... |